Fig. 2
From: Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
Cell viability was not affected by the presence of Pirfenidone. CT- and DD-derived fibroblasts derived from three different patient samples (N = 3/group) were incubated with different concentrations of PFD (0, 200, 400, 800 μg/ml), and the extracellular LDH release into the culture medium was measured as described in Materials and Methods. Data are shown as mean ± SEM of the averages of triplicate reads for each culture derived from the four different patient samples both for CT- and DD-derived fibroblasts. Ntx = no treatment (neither PFD nor TGF-β1 added control). Statistical analysis was performed using one-way ANOVA. *p < 0.05; **p < 0.01